Text Size

Complementary and Alternative Medicine for Urological Symptoms(CAMUS)

This study has been completed.
Sponsor:
Collaborators:
Office of Dietary Supplements (ODS)
National Center for Complementary and Alternative Medicine (NCCAM)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cornell University
New York University
Kaiser Permanente
Northwestern University
Queen's University
University of Colorado, Denver
University of Iowa
University of Maryland
University of Texas
Washington University School of Medicine
Yale University
Information provided by (Responsible Party):
Alan Cantor, PhD, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00603304
First received: December 20, 2007
Last updated: September 12, 2012
Last verified: September 2012
History of Changes
Results First Received: April 26, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator);   Primary Purpose: Treatment
Condition: Urological
Interventions: Drug: Saw Palmetto - first 24 weeks
Drug: Placebo - first 24 weeks
Drug: Saw Palmetto - weeks 24 - 48
Drug: Placebo - weeks 24 - 48
Drug: Saw Palmetto - weeks 48 - 72
Drug: Placebo - weeks 48 - 72

  Participant Flow
  Show Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Saw Palmetto Participants received one, two, and then three 320 mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract with dose escalations at 24 and 48 weeks.
Placebo Participants received either one, two, and then three 320 mg chocolate-colored placebo gelcaps with dose escalations at 24 and 48 weeks.
Total Total of all reporting groups

Baseline Measures
    Saw Palmetto     Placebo     Total  
Number of Participants  
[units: participants]
 		  183     186     369  
Age  
[units: participants]
 		     
<=18 years     0     0     0  
Between 18 and 65 years     123     125     248  
>=65 years     60     61     121  
Age  
[units: years]
Mean ± Standard Deviation 		  61.25  ± 8.72     60.70  ± 8.08     60.86  ± 8.38  
Gender  
[units: participants]
 		     
Female     0     0     0  
Male     183     186     369  
Region of Enrollment  
[units: participants]
 		     
United States     167     169     336  
Canada     16     17     33  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean and Standard Deviation of the Participant American Urological Association (AUA)Symptom Score Between Baseline and Week 72 for CAMUS Participants.   [ Time Frame: Baseline to 72 weeks ]
  Show Outcome Measure 1

2.  Secondary:   Participants Global Assessments of Improvement and Satisfaction at End of Study.   [ Time Frame: Baseline to 72 weeks ]
  Show Outcome Measure 2

3.  Secondary:   Benign Prostate Hyperplasia (BPH) Impact Index Score   [ Time Frame: Baseline to 72 weeks ]
  Show Outcome Measure 3

4.  Secondary:   International Prostate Symptom Score Quality of Life (IPSS QOL) Score   [ Time Frame: Baseline to 72 weeks ]
  Show Outcome Measure 4

5.  Secondary:   American Urological Association(AUA) Nocturia Item   [ Time Frame: Baseline to 72 weeks ]
  Show Outcome Measure 5

6.  Secondary:   Peak Uroflow   [ Time Frame: Baseline to 72 weeks ]
  Show Outcome Measure 6

7.  Secondary:   Post-void Residual   [ Time Frame: Baseline to 72 weeks ]
  Show Outcome Measure 7

8.  Secondary:   Prostate Specific Antigen (PSA) Level   [ Time Frame: Baseline to 72 weeks ]
  Show Outcome Measure 8

9.  Secondary:   International Index of Erectile Function (IIEF)Scale Score.   [ Time Frame: Baseline to 72 weeks ]
  Show Outcome Measure 9

10.  Secondary:   Male Sexual Health Questionnaire - Ejaculatory Domain (MSHQ-EjD) Scale Score.   [ Time Frame: Baseline to 72 weeks. ]
  Show Outcome Measure 10

11.  Secondary:   International Continence Society Male Incontinence Symptom (ICSmale IS) Score   [ Time Frame: Baseline to 72 weeks ]
  Show Outcome Measure 11

12.  Secondary:   Jenkins Sleep Scale Score   [ Time Frame: Baseline to 72 weeks ]
  Show Outcome Measure 12

13.  Secondary:   NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) Pain Scale   [ Time Frame: Baseline to 72 weeks ]
  Show Outcome Measure 13

14.  Secondary:   NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) Urinary Symptom Scale   [ Time Frame: Baseline to 72 weeks ]
  Show Outcome Measure 14

15.  Secondary:   NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) Quality of Life (QOL)Scale   [ Time Frame: Baseline to 72 weeks ]
  Show Outcome Measure 15


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Dr. Alan Cantor
Organization: University of Alabama at Birmingham
phone: (205) 934-6887
e-mail: acantor@uab.edu


Publications of Results:

Other Publications:

Publications automatically indexed to this study:


Responsible Party: Alan Cantor, PhD, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT00603304     History of Changes
Obsolete Identifiers: NCT00097136
Other Study ID Numbers: X021004002, U01DK063788, Tracking # (UAB) 000175609
Study First Received: December 20, 2007
Results First Received: April 26, 2012
Last Updated: September 12, 2012
Health Authority: United States: Food and Drug Administration